

Volume 761
June 12, 1995

STEROID RECEPTORS AND ANTIHORMONES ^a

Editors and Conference Chairs

DAVID HENDERSON, DANIEL PHILIBERT, ARUN K. ROY, AND GEORGES TEUTSCH

CONTENTS

Preface. <i>By</i> THE EDITORS	xi
Part I. General Overview	
Steroid Hormone Antagonists: Summary and Future Challenges. <i>By</i> ELWOOD V. JENSEN	1
General Structure-Activity Correlations of Antihormones. <i>By</i> G. TEUTSCH, F. NIQUE, G. LEMOINE, F. BOUCHOUX, E. CÉRÈDE, D. GOFFLO, and D. PHILIBERT	5
Part II. Steroid Receptor Structure and Function	
Nuclear Hormone Receptors Activate Direct, Inverted, and Everted Repeats. <i>By</i> BARRY MARC FORMAN and RONALD M. EVANS ...	29
Ubiquitous Receptor: Structures, Immunocytochemical Localization, and Modulation of Gene Activation by Receptors for Retinoic Acids and Thyroid Hormones. <i>By</i> CHING SONG, RICHARD A. HIIPAKKA, JOHN M. KOKONTIS, and SHUTSUNG LIAO	38
Connection between Immunosuppressants and Steroids via HSP90. <i>By</i> ETIENNE-EMILE BAULIEU	50
Part III. Receptor-Mediated Antihormone Action	
Section 1. Antagonism of Androgen Action	
Local Inhibition of Sebaceous Gland Growth by Topically Applied RU 58841. <i>By</i> JONATHAN R. MATIAS and MARTINE GAILLARD	56
Sex Steroids and Epidermal Growth Factor in Benign Prostatic Hyperplasia (BPH). <i>By</i> F. SCIARRA	66

^aThis volume contains the papers from a conference entitled *Steroid Receptors and Antihormones*, which was held by the New York Academy of Sciences in Dallas, Texas on September 20-23, 1994.

Casodex: Preclinical Studies and Controversies. <i>By</i> BARRY J. A. FURR	79
Regulation of Androgen Action by Receptor Gene Inhibition. <i>By</i> C. S. SONG, M. H. JUNG, P. C. SUPAKAR, S. CHEN, R. L. VELLANOWETH, B. CHATTERJEE, and A. K. ROY	97
Section 2. Estrogen Antagonists	
A New Interpretation of Antiestrogen Action. <i>By</i> ANNEMARIE HEDDEN, VOLKMAR MÜLLER, and ELWOOD V. JENSEN	109
Cellular Mechanisms Which Distinguish between Hormone- and Antihormone-Activated Estrogen Receptor. <i>By</i> DONALD P. MCDONNELL, SHARON L. DANA, PATRICIA A. HOENER, BENJAMIN A. LIEBERMAN, MARKUS O. IMHOF, and ROBERT B. STEIN	121
A Mutant Receptor as a Mechanism of Drug Resistance to Tamoxifen Treatment. <i>By</i> V. CRAIG JORDAN, WILLIAM H. CATHERINO, and DOUGLAS M. WOLF	138
Responses to Pure Antiestrogens (ICI 164384, ICI 182780) in Estrogen-Sensitive and -Resistant Experimental and Clinical Breast Cancer. <i>By</i> R. I. NICHOLSON, J. M. W. GEE, D. L. MANNING, A. E. WAKELING, M. M. MONTANO, and B. S. KATZENELLENBOGEN	148
Exploration of the Therapeutic Potential of the Antiestrogen RU 58668 in Breast Cancer Treatment. <i>By</i> P. VAN DE VELDE, F. NIQUE, J. BRÉMAUD, M-C. HAMEAU, D. PHILIBERT, and G. TEUTSCH	164
Studies on Heterocycle-Based Pure Estrogen Antagonists. <i>By</i> E. VON ANGERER, C. BIBERGER, and S. LEICHTL	176
Section 3. Antiprogestins	
Pharmacological Properties of a New Selective Antiprogestagen: Org 33628. <i>By</i> H. J. KLOOSTERBOER, G. H. DECKERS, M. E. DE GOOYER, R. DIJKEMA, E. O. M. ORLEMANS, and W. G. E. J. SCHOONEN	192
Mechanism of Action of Antiprogestins in the Pregnant Uterus. <i>By</i> K. CHWALISZ, K. STÖCKEMANN, U. FUHRMANN, K. H. FRITZEMEIER, A. EINSPIANIER, and R. E. GARFIELD	202
Differentiation Therapy with Progesterone Antagonists. <i>By</i> HORST MICHNA, KARSTEN PARCZYK, MARTIN R. SCHNEIDER, and YUKISHIGE NISHINO	224

Clinical Uses of Mifepristone (MFP). <i>By</i> ANDRÉ ULMANN, RÉMI PEYRON, and LOUISE SILVESTRE	248
--	-----

Section 4. Adrenocorticoid Antagonists

Glucocorticoid Antagonist RU 486 Reverses Agonist-Induced Apoptosis and C-Myc Repression in Human Leukemic CEM-C7 Cells. <i>By</i> E. B. THOMPSON, R. THULASI, M. F. SAEED, and B. H. JOHNSON	261
---	-----

The Influence of Antigluco-corticoids on Stress and Shock. <i>By</i> GEORGE LÁZÁR, GEORGE LÁZÁR, JR., ELIZABETH HUSZTIK, ERNÓ DUDA, and MANJUL K. AGARWAL	276
---	-----

The Glucocorticoid Receptor and RU 486 in Man. <i>By</i> CHRISTOPH M. BAMBERGER and GEORGE P. CHROUSOS	296
--	-----

Drospirenone: a Novel Progestogen with Antimineralocorticoid and Antiandrogenic Activity. <i>By</i> PETER MUHN, ULRIKE FUHRMANN, KARL-HEINRICH FRITZEMEIER, ROLF KRATTENMACHER, and EKKEHARD SCHILLINGER	311
--	-----

Poster Papers

Effects of Forskolin on Steroid Receptors. <i>By</i> N. RIBARAC-ŠTEPIĆ, Z. ŽAKULA, E. ISENOVIĆ, and D. T. KANAZIR	336
---	-----

Molecular Mechanism of Inhibition of Steroid Dehydrogenases by Licorice-Derived Steroid Analogs in Modulation of Steroid Receptor Function. <i>By</i> D. GHOSH, Z. WAWRZAK, V. PLETNEV, M. ERMAN, W. L. DUAX, W. PANGBORN, D-W. ZHU, F. LABRIE, and S-X. LIN	341
--	-----

Biochemical Significance of the 6-s-cis Conformation of the Steroid Hormone 1 α ,25-Dihydroxyvitamin D ₃ Based on the Provitamin D Skeleton. <i>By</i> WILLIAM H. OKAMURA, M. MARK MIDLAND, ANTHONY W. NORMAN, MARION W. HAMMOND, MURRAY C. DORMANEN, and ILKA NEMERE	344
---	-----

Effects of a New Vitamin D Analog, EB 1089, on Osteoblastic Cells. <i>By</i> PEKKA H. MÄENPÄÄ, TIINA JÄÄSKELÄINEN, and ANITTA MAHONEN	349
---	-----

Effects of Androgens and Antiandrogens on the Conformation of the Androgen Receptor. <i>By</i> C. W. KUIL and E. MULDER	351
---	-----

Raloxifene is a Tissue-Selective Agonist/Antagonist That Functions through the Estrogen Receptor. <i>By R. FUCHS-YOUNG, A. L. GLASEBROOK, L. L. SHORT, M. W. DRAPER, M. K. RIPPY, H. W. COLE, D. E. MAGEE, J. D. TERMINE, and H. U. BRYANT...</i>	355
Inhibition of Nuclear Transport Is Not Essential for Inhibition of Receptor Function by the Type II Estrogen Antagonist ICI-164,384. <i>By RICHARD J. MIKSICEK, CONNIE LEE, KAREN TOPP-RAPIEJKO, and SHERRY NEFF.....</i>	361
Mood Disorder in Women with Early Breast Cancer Taking Tamoxifen, an Estradiol Receptor Antagonist: an Expected or Unexpected Effect? <i>By S. SHARIFF, C. E. CUMMING, A. LEES, M. HANDMAN, and D. C. CUMMING.....</i>	365
Diethylstilbestrol (DES)-Related Endocrine Disturbances in Women: a Story with No End, Yet. <i>By JOHANNA ASSIES, JAN VONK, OTTO BLEKER, and LAMBERTUS LUMEY.....</i>	369
Estrogen/Antiestrogen Responsiveness in an <i>In Vivo/In Vitro</i> Model for Myometrial Tumorigenesis. <i>By S. R. HOWE, J. I. EVERITT, M. M. GOTTARDIS, and C. WALKER.....</i>	373
Vascular Endothelial Growth Factor (VEGF) in Primate Endometrium: Immunohistochemical Patterns during the Cycle and after Chronic RU 486 Treatment in Cynomolgus Monkeys. <i>By R. R. GREB, R. BUKOWSKI, J. G. HSIU, R. F. WILLIAMS, G. D. HODGEN, and A. L. GOODMAN.....</i>	376
Synthesis and Biological Activity of Novel Nonsteroidal Progesterone Receptor Antagonists. <i>By LAWRENCE G. HAMANN, LUC J. FARMER, MICHAEL G. JOHNSON, MARK E. GOLDMAN, DALE E. MAIS, ALENUSH DAVTIAN, STEVEN L. BENDER, and TODD K. JONES.....</i>	383
Glucocorticoid Receptors in Mouse Melanoma Cells. <i>By A. RISTIĆ-FIRA, R. DJORDJEVIĆ-MARKOVIĆ, M. RADOJČIĆ, N. RIBARAC-STEPIĆ, and D. T. KANAZIR.....</i>	388
The Effects of Glucocorticoid Receptor (GR) Blockade by RU 38486 and GR Protection by GTT on Hemorrhagic Shock in Rats. <i>By XU REN-BAO, WU JAN, LU JUN HUA, SHI HAN PIN, LIN CHANG QUAN, and GONG XIAO QI.....</i>	391
Anabolic Steroids Induce Skeletal Muscle Injury and Immediate Early Gene Expression through a Receptor-Independent Mechanism. <i>By SAWSAN R. ABU-SHAKRA and FRANK C. NACHTMAN.....</i>	395
Commonly Used Therapeutic Doses of Glucocorticoids Impair Explicit Memory. <i>By P. A. KEENAN, M. W. JACOBSON, R. M. SOLEYMANI, and J. W. NEWCOMER.....</i>	400

Point Mutations in the 90-kDa Heat Shock Protein Binding Region of the Glucocorticoid Receptor Affect the Functional Characteristics of the Receptor. By CLAUDIO A. CAAMAÑO, M. INÉS MORANO, FRIEDRICH C. DALMAN, MARY T. HOVERSTEN, STANLEY J. WATSON, WILLIAM B. PRATT, and HUDA AKIL	403
Dexamethasone Downregulates Mineralocorticoid Receptors in A6 Amphibian Kidney Cells in Tissue Culture. By RODNEY D. HAGLEY and CHARLES O. WATLINGTON.	405
Subject Index	409
Index of Contributors	415

Financial assistance was received from:

Supporters

- INSTITUT SCIENTIFIQUE ROUSSEL
- SCHERING AG PHARMACEUTICAL RESEARCH

Contributors

- BERLEX BIOSCIENCES
- IMMUNEX RESEARCH AND DEVELOPMENT CORPORATION
- THE R. W. JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE
- MERCK RESEARCH LABORATORIES
- ORGANON INTERNATIONAL B.V.
- PFIZER CENTRAL RESEARCH

The New York Academy of Sciences believes it has a responsibility to provide an open forum for discussion of scientific questions. The positions taken by the participants in the reported conferences are their own and not necessarily those of the Academy. The Academy has no intent to influence legislation by providing such forums.